• +1-646-491-9876
    • +91-20-67278686

    Search

    Fibromyalgia-Pipeline Review H2 2017

    Fibromyalgia-Pipeline Review H2 2017

    • Report Code ID: RW0001881466
    • Category Life Sciences
    • No. of Pages 64
    • Publication Month Jul-17
    • Publisher Name Global Markets Direct
    Fibromyalgia-Pipeline Review H2 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Fibromyalgia-Pipeline Review H2 2017 provides an overview of the Fibromyalgia (Central Nervous System) pipeline landscape.

    Fibromyalgia is a disorder characterized by widespread musculoskeletal pain accompanied by fatigue sleep memory and mood issues. Symptoms include fatigue depression headaches and pain or cramping in the lower abdomen. The predisposing factors include family history rheumatoid arthritis or lupus. Treatment includes pain relievers antidepressants and anti-seizure drugs.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Fibromyalgia-Pipeline Review H2 2017 provides comprehensive information on the therapeutics under development for Fibromyalgia (Central Nervous System) complete with analysis by stage of development drug target mechanism of action (MoA) route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics its complete research and development history and latest news and press releases.

    The Fibromyalgia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Fibromyalgia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes the molecules developed by Companies in Pre-Registration Phase III Phase II Phase I and Preclinical stages are 1 2 5 3 and 2 respectively. Similarly the Universities portfolio in Preclinical stages comprises 1 molecules respectively.

    Fibromyalgia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases company/university websites clinical trial registries conferences SEC filings investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Fibromyalgia (Central Nervous System) .
    - The pipeline guide reviews pipeline therapeutics for Fibromyalgia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise product description descriptive licensing and collaboration details R&D brief MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Fibromyalgia (Central Nervous System) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Fibromyalgia (Central Nervous System) therapeutics based on mechanism of action (MoA) drug target route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Fibromyalgia (Central Nervous System)

    Reasons to buy

    - Procure strategically important competitor information analysis and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Fibromyalgia (Central Nervous System) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Fibromyalgia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Fibromyalgia-Overview
    Fibromyalgia-Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Fibromyalgia-Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Fibromyalgia-Companies Involved in Therapeutics Development
    Astellas Pharma Inc
    Daiichi Sankyo Company Ltd
    Immune Therapeutics Inc
    Innovative Med Concepts LLC
    Intec Pharma ltd
    Jiangsu Hengrui Medicine Co Ltd
    KPI Therapeutics Inc
    Merck & Co Inc
    Pfizer Inc
    Switch Biotech LLC
    Zynerba Pharmaceuticals Inc
    Fibromyalgia-Drug Profiles
    (cannabidiol + dronabinol)-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (celecoxib + famciclovir)-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AS-1069562-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ASP-0819-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ASP-8062-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    mirogabalin besylate-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    mirtazapine ODT-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    naltrexone hydrochloride-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Peptide to Block Voltage-Dependent N-Type Calcium Channel for Central Nervous System-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pregabalin CR-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pregabalin SR-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SWT-06101-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    U-2902-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ZYN-001-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Fibromyalgia-Dormant Projects
    Fibromyalgia-Discontinued Products
    Fibromyalgia-Product Development Milestones
    Featured News & Press Releases
    Jun 30 2017 Daiichi Sankyo Announces Top-line Results from Phase 3 Global Clinical Development Program Evaluating Mirogabalin in Pain Syndromes
    Jun 26 2017 Zynerba Pharmaceuticals Initiates ZYN001 Phase 1 Clinical Program
    Mar 22 2017 Intec Pharma Initiates Phase I Trial of Accordion Pill for Cannabinoid Therapies
    Mar 07 2017 Journal of Pain Research Publishes Results of PRID-201 a successful Phase 2 Trial using IMC-1 for the Treatment of Fibromyalgia
    Oct 17 2016 Zynerba Provides Clinical Update for Lead Development Candidate ZYN001
    Jan 28 2016 Innovative Med Concepts Announces Receipt of FDA Fast Track Designation for IMC-1 a Novel Treatment for Fibromyalgia
    Feb 04 2015 Daiichi Sankyo Announces First Patients in Large-scale Multi-national Phase 3 Clinical Programs for Mirogabalin
    Nov 18 2014 Novel Fibromyalgia Treatment Shows Promise In Study
    Nov 27 2012 Intellipharmaceutics Announces Results Of Initial Phase I Clinical Trial Of Controlled-release Pregabalin
    Nov 19 2012 Pfizer Reports Top-line Results Of Phase III Study Evaluating Pregabalin Controlled-release As Treatment For Patients With Fibromyalgia
    Jul 23 2012 Pfizer Reports Top-Line Results Of EU Post-Authorization Safety And Efficacy Study Of Lyrica's Discontinuation Effects In Patients With Generalized Anxiety Disorder
    Feb 02 2009 UCB Announces Top-Line Outcomes For Proof-Of-Concept Studies
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Fibromyalgia H2 2017
    Number of Products under Development by Companies H2 2017
    Number of Products under Development by Universities/Institutes H2 2017
    Products under Development by Companies H2 2017
    Products under Development by Universities/Institutes H2 2017
    Number of Products by Stage and Target H2 2017
    Number of Products by Stage and Mechanism of Action H2 2017
    Number of Products by Stage and Route of Administration H2 2017
    Number of Products by Stage and Molecule Type H2 2017
    Fibromyalgia-Pipeline by Astellas Pharma Inc H2 2017
    Fibromyalgia-Pipeline by Daiichi Sankyo Company Ltd H2 2017
    Fibromyalgia-Pipeline by Immune Therapeutics Inc H2 2017
    Fibromyalgia-Pipeline by Innovative Med Concepts LLC H2 2017
    Fibromyalgia-Pipeline by Intec Pharma ltd H2 2017
    Fibromyalgia-Pipeline by Jiangsu Hengrui Medicine Co Ltd H2 2017
    Fibromyalgia-Pipeline by KPI Therapeutics Inc H2 2017
    Fibromyalgia-Pipeline by Merck & Co Inc H2 2017
    Fibromyalgia-Pipeline by Pfizer Inc H2 2017
    Fibromyalgia-Pipeline by Switch Biotech LLC H2 2017
    Fibromyalgia-Pipeline by Zynerba Pharmaceuticals Inc H2 2017
    Fibromyalgia-Dormant Projects H2 2017
    Fibromyalgia-Dormant Projects H2 2017 (Contd..1) H2 2017
    Fibromyalgia-Discontinued Products H2 2017

    List of Figures

    Number of Products under Development for Fibromyalgia H2 2017
    Number of Products under Development by Companies H2 2017
    Number of Products by Top 10 Targets H2 2017
    Number of Products by Stage and Top 10 Targets H2 2017
    Number of Products by Top 10 Mechanism of Actions H2 2017
    Number of Products by Stage and Top 10 Mechanism of Actions H2 2017
    Number of Products by Routes of Administration H2 2017
    Number of Products by Stage and Routes of Administration H2 2017
    Number of Products by Molecule Types H2 2017
    Number of Products by Stage and Molecule Types H2 2017
    Astellas Pharma Inc
    Daiichi Sankyo Company Ltd
    Immune Therapeutics Inc
    Innovative Med Concepts LLC
    Intec Pharma ltd
    Jiangsu Hengrui Medicine Co Ltd
    KPI Therapeutics Inc
    Merck & Co Inc
    Pfizer Inc
    Switch Biotech LLC
    Zynerba Pharmaceuticals Inc

    Request for Sample

    Report Url https://www.reportsweb.com//fibromyalgia-pipeline-review-h2-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//fibromyalgia-pipeline-review-h2-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//fibromyalgia-pipeline-review-h2-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments